Recruiting
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
I4V-MC-JAHW - ClinicalTrials.gov - NCT04088409
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years old.
How long will I be in the trial?
The study will last about 284 weeks and may include 30 visits.
Recruiting
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
I4V-MC-JAHW - ClinicalTrials.gov - NCT04088409
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years old.
How long will I be in the trial?
The study will last about 284 weeks and may include 30 visits.
Key Requirements
Age :
2-17
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
2-17
Sex
All
Participants must
Participants must have a diagnosis of JIA-U or chronic anterior antinuclear antibody (ANA) positive uveitis without systemic features
Participants must have active anterior uveitis
Participants must have an inadequate response or intolerance to MTX
Participants must be on a stable dose of corticosteroid eye drops
Participants and their partners must be willing to use two forms of birth control
Participants must NOT
Participants must not have of any autoimmune inflammatory condition other than JIA
Participants must not have had eye surgery within the 3 months
Participants must not have an infection
Participants must not have hepatitis B or tuberculosis (TB)
Trial Summary
Conditions the trial is for
Uveitis, Pediatric Uveitis
What the trial is testing?
Baricitinib, Adalimumab
Could I receive a Placebo?
no
Enrollment Goal
40
Trial Dates
October 2019 - December 2027
Trial Phase
3
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
2-17
Sex
All
Participants must
Participants must have a diagnosis of JIA-U or chronic anterior antinuclear antibody (ANA) positive uveitis without systemic features
Participants must have active anterior uveitis
Participants must have an inadequate response or intolerance to MTX
Participants must be on a stable dose of corticosteroid eye drops
Participants and their partners must be willing to use two forms of birth control
Participants must NOT
Participants must not have of any autoimmune inflammatory condition other than JIA
Participants must not have had eye surgery within the 3 months
Participants must not have an infection
Participants must not have hepatitis B or tuberculosis (TB)
Trial Summary
Conditions the trial is for
Uveitis, Pediatric Uveitis
What the trial is testing?
Baricitinib, Adalimumab
Could I receive a Placebo?
no
Enrollment Goal
40
Trial Dates
October 2019 - December 2027
Trial Phase
3
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Resources
